Evidence map›Paper›PMID 32039919›Full record

ArticleThe Journal of clinical investigation2020

Proliferative, degradative smooth muscle cells promote aortic disease.

Maarten Hulsmans, Matthias Nahrendorf

Open access · bronzeAbstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Chronic Edema Associated with Cor Pulmonale in Cattle.Animals : an open access journal from MDPI · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Maarten HulsmansCenter for Systems Biology, Department of Radiology, and.
Matthias NahrendorfCenter for Systems Biology, Department of Radiology, and.
Center for Systems Biology · USHarvard University · US

Funding

Imaging organ system interfaces in ischemic heart diseaseR35HL139598 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHRENDORF, MATTHIAS · 2018 to 2024
$6.9M
Quantitative nanoparticle imaging of macrophagesR01HL131495 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHRENDORF, MATTHIAS, WEISSLEDER, MD, PHD, RALPH · 2017 to 2020
$2.7M
Interfering with the macrophage life cycle of atherosclerosisR01HL125428 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ANDERSON, DANIEL G, NAHRENDORF, MATTHIAS · 2017 to 2020
$1.9M
NHLBI NIH HHS R01 HL125428NHLBI NIH HHS R01 HL131495NHLBI NIH HHS R35 HL139598
6 · The paper itself

Abstract

Aneurysms are common in the abdominal and thoracic regions of the aorta and can cause death due to dissection or rupture. Traditionally, thoracic aortic aneurysms have been labeled as a degenerative disease, characterized by alterations in extracellular matrix and loss of smooth muscle cells (SMCs) in the medial layer of the aortic wall. In this issue of the JCI, Li and colleagues introduce an unconventional concept by demonstrating that mTOR-dependent proliferative SMCs render the aortic wall vulnerable to dilatation and dissection rather than prevent disease progression. These vascular SMCs, termed degradative SMCs, compromise the medial properties and function of the aortic wall by enhanced proteolytic and phagocytic activity; however, the cells do not transdifferentiate into macrophages. The degradative SMC phenotype also worsens atherosclerotic disease and could thus be considered as a therapeutic target for diverse aortic diseases.

Indexed as

Aortic DiseasesMuscle, Smooth, VascularHumansMyocytes, Smooth MusclePhenotypeTOR Serine-Threonine KinasesMTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID32039919
PMCPMC7269557
OpenAlexW3004810094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.